Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07602517 · ClinicalTrials.gov registry record
Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis
A clinical trial, sponsored by NYU Langone Health.
- Not yet
- Registry status
- 75
- Enrollment target
NCT07602517 is a clinical trial that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 75 participants.
The verdict
NCT07602517 has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- 75 participants
- Enrollment target
Study Summary
This is an observational study of a prospective cohort of guselkumab-initiating Crohn's Disease (CD) and Ulcerative Colitis (UC) patients to identify new or incident spondyloarthritis. This study will include adult patients aged 18-75 with IBD who are undergoing guselkumab intravenous or subcutaneous induction over a 1-year timeframe.
Interventions
- DRUG Guselkumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-05-20 |
| Est. Completion | 2029-05-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07602517
The ClinicalTrials.gov registry entry for NCT07602517 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guselkumab is the first listed.
NCT07602517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07602517 about?
NCT07602517 is a clinical study titled "Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis". This is an observational study of a prospective cohort of guselkumab-initiating Crohn's Disease (CD) and Ulcerative Colitis (UC) patients to identify new or incident spondyloarthritis. This study will include adult patients aged 18-75 with IBD who are undergoing guselkumab intravenous or subcutaneou...
What is the current status of trial NCT07602517?
This trial is currently not yet recruiting. The enrollment target is 75 participants. The study started on 2026-05-20. Estimated completion is 2029-05-20.
What interventions are being tested in trial NCT07602517?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT07602517?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.